BR112014032526A2 - composto, e composição farmacêutica - Google Patents

composto, e composição farmacêutica

Info

Publication number
BR112014032526A2
BR112014032526A2 BR112014032526A BR112014032526A BR112014032526A2 BR 112014032526 A2 BR112014032526 A2 BR 112014032526A2 BR 112014032526 A BR112014032526 A BR 112014032526A BR 112014032526 A BR112014032526 A BR 112014032526A BR 112014032526 A2 BR112014032526 A2 BR 112014032526A2
Authority
BR
Brazil
Prior art keywords
ampk
compound
pharmaceutical composition
liver
treatment
Prior art date
Application number
BR112014032526A
Other languages
English (en)
Other versions
BR112014032526B1 (pt
Inventor
Charon Christine
Cravo Daniel
Lepifre Franck
Durand Jean-Denis
Faveriel Laurent
Hallakou-Bozec Sophie
Bolze Sébastien
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of BR112014032526A2 publication Critical patent/BR112014032526A2/pt
Publication of BR112014032526B1 publication Critical patent/BR112014032526B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo composto, e composição farmacêutica ativadores de ampk e seus usos terapêuticos. a invenção se refere a compostos que são ativadores diretos de ampk (proteína quinase ativada por amp) e seus usos no tratamento de distúrbios regulados pela ativação de ampk. por exemplo, os compostos de acordo com a invenção são úteis para o tratamento de diabetes, síndrome metabólica, obesidade, doenças hepáticas, esteatose hepática, doença hepática gordurosa não alcoólica (nafld), esteato-hepatite não alcoólica (nash), fibrose hepática, dislipidemia, hipertrigliceridemia, hipercolesterolemia, inflamação, câncer, doenças cardiovasculares, aterosclerose, hipertensão arterial, retinopatias ou neuropatias. 1/1
BR112014032526-0A 2012-06-29 2013-06-28 Compostos ativadores de ampk e composição farmacêutica dos mesmos BR112014032526B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305775.4 2012-06-29
EP12305775.4A EP2679591A1 (en) 2012-06-29 2012-06-29 Thienopyridone derivatives useful as activators of AMPK
PCT/EP2013/063741 WO2014001554A1 (en) 2012-06-29 2013-06-28 Thienopyridone derivatives useful as activators of ampk

Publications (2)

Publication Number Publication Date
BR112014032526A2 true BR112014032526A2 (pt) 2017-06-27
BR112014032526B1 BR112014032526B1 (pt) 2022-11-01

Family

ID=48703549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032526-0A BR112014032526B1 (pt) 2012-06-29 2013-06-28 Compostos ativadores de ampk e composição farmacêutica dos mesmos

Country Status (26)

Country Link
US (1) US9284329B2 (pt)
EP (2) EP2679591A1 (pt)
JP (1) JP5972460B2 (pt)
KR (1) KR101704448B1 (pt)
CN (2) CN107266467A (pt)
AU (1) AU2013283239B2 (pt)
BR (1) BR112014032526B1 (pt)
CA (1) CA2876789C (pt)
CY (1) CY1118213T1 (pt)
DK (1) DK2867240T3 (pt)
EA (1) EA026300B1 (pt)
ES (1) ES2603737T3 (pt)
HR (1) HRP20161482T1 (pt)
HU (1) HUE030946T2 (pt)
IL (1) IL236221A (pt)
IN (1) IN2014MN02661A (pt)
LT (1) LT2867240T (pt)
ME (1) ME02537B (pt)
MX (1) MX359221B (pt)
PL (1) PL2867240T3 (pt)
PT (1) PT2867240T (pt)
RS (1) RS55308B1 (pt)
SI (1) SI2867240T1 (pt)
SM (1) SMT201600418B (pt)
WO (1) WO2014001554A1 (pt)
ZA (1) ZA201500593B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105078992B (zh) * 2014-05-23 2017-11-21 资元堂生物科技股份有限公司 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途
CN104910129A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 含六甲基苯环和卤代苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104910130A (zh) * 2015-06-23 2015-09-16 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和氨基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN105541715B (zh) * 2016-02-02 2019-04-09 浙江工业大学 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用
KR101925020B1 (ko) 2017-04-21 2018-12-04 연세대학교 산학협력단 Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물
EA202091897A1 (ru) * 2018-02-08 2020-10-27 Энио Фарма Неконденсированные производные тиофена и их применение
CN108516972A (zh) * 2018-05-30 2018-09-11 王丽萍 一种goat抑制剂及其在肥胖和糖尿病中的应用
EP3880683B1 (en) * 2018-11-16 2023-11-01 Poxel Monohydrate potassium salt of a thienopyridone derivative and its preparation process
US20220184172A1 (en) * 2019-04-19 2022-06-16 The Regents Of The University Of California Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
WO2021037702A1 (en) 2019-08-28 2021-03-04 Poxel Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
JP2023503279A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ジベンゾピランａｍｐｋ活性化剤化合物、組成物、方法、及びその使用
MX2022011938A (es) * 2020-03-26 2023-01-04 Poxel Uso de un derivado de tienopiridona en el tratamiento de la adrenoleucodistrofia o adrenomieloneuropatia.
WO2021198284A1 (en) 2020-03-30 2021-10-07 Poxel Use of a thienopyridone derivative in the treatment of cardiovascular diseases
EP4125885A1 (en) 2020-03-30 2023-02-08 Poxel Use of a thienopyridone derivative in the treatment of diabetic nephropathy
EP4125887B1 (en) 2020-04-02 2024-02-07 Poxel Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd)
WO2021204751A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
WO2021204755A1 (en) 2020-04-06 2021-10-14 Poxel Pharmaceutical combination for the treatment of liver diseases
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
BRPI0910439B8 (pt) 2008-04-11 2021-05-25 Merck Patent Gmbh derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
MX2010011916A (es) 2008-05-05 2010-11-26 Merck Patent Gmbh Derivados de tienopiridonas como activadores de proteinas cinasa activados por amp (ampk).

Also Published As

Publication number Publication date
CN104395319A (zh) 2015-03-04
RS55308B1 (sr) 2017-03-31
JP2015521651A (ja) 2015-07-30
EP2867240B1 (en) 2016-09-14
IL236221A (en) 2017-12-31
JP5972460B2 (ja) 2016-08-17
EA201500064A1 (ru) 2015-08-31
PL2867240T3 (pl) 2017-02-28
EA026300B1 (ru) 2017-03-31
AU2013283239B2 (en) 2016-01-28
ZA201500593B (en) 2016-01-27
KR101704448B1 (ko) 2017-02-08
CN104395319B (zh) 2017-10-27
DK2867240T3 (en) 2016-12-05
SMT201600418B (it) 2017-01-10
US9284329B2 (en) 2016-03-15
HUE030946T2 (en) 2017-06-28
CA2876789C (en) 2017-01-31
MX2014016107A (es) 2015-11-16
AU2013283239A1 (en) 2015-01-22
EP2679591A1 (en) 2014-01-01
SI2867240T1 (sl) 2017-01-31
ES2603737T3 (es) 2017-03-01
WO2014001554A1 (en) 2014-01-03
PT2867240T (pt) 2016-11-24
KR20150033709A (ko) 2015-04-01
BR112014032526B1 (pt) 2022-11-01
CY1118213T1 (el) 2017-06-28
ME02537B (me) 2017-02-20
IN2014MN02661A (pt) 2015-08-28
LT2867240T (lt) 2016-12-27
CA2876789A1 (en) 2014-01-03
MX359221B (es) 2018-09-18
IL236221A0 (en) 2015-02-01
EP2867240A1 (en) 2015-05-06
HRP20161482T1 (hr) 2016-12-30
CN107266467A (zh) 2017-10-20
US20150166566A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
BR112014032526A2 (pt) composto, e composição farmacêutica
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
BR112013021236A2 (pt) composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112013032375A2 (pt) conjugado compreendendo oxintomodulina e um fragmento de imunoglobulina, e seus usos
CL2008003582A1 (es) Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash).
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BRPI0520669A2 (pt) dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina
BR112015011403A2 (pt) uso de akkermansia para o tratamento de distúrbios metabólicos
BR112012016330B8 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos
WO2014062720A3 (en) Methods of treating cancer
CL2008003407A1 (es) Compuestos derivados de aril- y heteroarilcarbonilo de heterobiciclo sustituido; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento y/o prevencion de trastornos metabolicos, mediado por la inhibicion de la enzima hsd-1.
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112014027697A2 (pt) polipeptídeos que se ligam ao receptor de quimiocina
BR112014016810A8 (pt) composições e métodos para tratamento de distúrbios metabólicos
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
BR112013005622A2 (pt) heteroaril metil amidas
CL2007001945A1 (es) Compuestos derivados de alquilpiridazina, inhibidores de 11 beta-hsd1; proceso de obtencion de los compuestos; composicion farmaceutica que los comprenden; y usos en el tratamiento de la diabetes, obesidad, trastorno de ingestion de comida, dislipide
MX340985B (es) Compuestos de n-heteroarilo.
MX2023005550A (es) Inhibidores de diclorofenol hsd17b13 y usos de los mismos.
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
WO2016085321A3 (en) Composition comprising a pentose and polyphenolic compound

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2013, OBSERVADAS AS CONDICOES LEGAIS